YULINXUS

WIPO WIPO 2022

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark YULINXUS was filed as Word mark on 02/23/2022 at the World Intellectual Property Organization.

Trademark Details Last update: July 19, 2023

Trademark form Word mark
File reference 1672534
Countries Australia Brazil Canada Switzerland China Colombia European Community United Kingdom Georgia India Japan South Korea Mexico New Zealand Serbia Russia Singapore Turkey Ukraine
Base trademark US No. 90906318, August 27, 2021
Application date February 23, 2022
Expiration date February 23, 2032

Trademark owner

12830 El Camino Real, Suite 400
San Diego CA 92130
US

Trademark representatives

Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW US

goods and services

05 Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders
35 Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals
42 Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
44 Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Trademark history

Date Document number Area Entry
July 17, 2023 2023/29 Gaz KR Rejection
May 30, 2023 2023/22 Gaz CH Rejection
May 25, 2023 2023/21 Gaz JP Rejection
May 19, 2023 2023/21 Gaz GE Rejection
May 10, 2023 2023/21 Gaz CO RAW: Rule 18ter(2)(ii) GP following a provisional refusal
May 5, 2023 2023/19 Gaz UA Rejection
April 19, 2023 2023/17 Gaz BR Rejection
March 31, 2023 2023/17 Gaz SG Rejection
February 6, 2023 2023/6 Gaz CN Rejection
January 16, 2023 2023/3 Gaz RS Rejection
January 5, 2023 2023/1 Gaz NZ Rejection
December 1, 2022 2022/48 Gaz EM Rejection
November 28, 2022 2022/48 Gaz TR Rejection
October 11, 2022 2022/41 Gaz RU Rejection
October 6, 2022 2022/40 Gaz GB Rejection
October 4, 2022 2022/41 Gaz CO Rejection
September 24, 2022 2022/39 Gaz AU Rejection
February 23, 2022 2022/26 Gaz US Registration

ID: 141672534